UNSPSC 51101934: Moxipraquine

This classification denotes an antimalarial agent with the molecular formula C24H38N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GP95SEQ1AQ, chemically known as 1-piperazinepropanol, 4-(6-((6-methoxy-8-quinolyl)amino)hexyl)-alpha-methyl- but generally known as moxipraquine, which bears US NIH Compound Identifier 72091. European Medicines Agency schedules Moxipraquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09088MIG.

UNSPSC 51101934 Moxipraquine, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmaceutical programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals for cooperative purchasing — none of which involve moxipraquine (an anti-malarial pharmaceutical with limited domestic public-sector use). The code shows little relevant recent activity, and the tagging mismatch suggests either data-quality issues in the source system or a labeling error in how opportunities were classified.

The issuing bodies across the recent opportunities span state health agencies (Texas Health and Human Services Commission), cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states), county health departments (Seminole County, Florida), and municipal first-responder departments (City of Tampa Fire Department). Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division (response deadline March 13, 2026), designated as a sheltered market for certified Small Local Business Enterprises with an estimated contract value of $700,000; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon (response deadline March 26, 2026). Geographic activity centers on Florida, Texas, and the Upper Midwest, with cooperative purchasing extending across multiple jurisdictions. Bidders pursuing opportunities under this code should verify alignment with actual procurement scope before submitting, as the code's nominal category does not reflect the work being solicited.